JOINT EVALUATION Sample Clauses

JOINT EVALUATION. Clause 21.01 Provisions, which form the basis of the Joint Job Evaluation Plan, are contained in the Collective Agreement and Job Evaluation Manual. The Job Evaluation Manual shall form an integral part of the Collective Agreement. Clause 21.02 The Plan covers all jobs falling under the scope of the Collective Agreement, in the O.C.T. Unit, Schedule "A". Clause 21.03 The parties further agree that no employee shall have their wages reduced because of the implementation of the Joint Job Evaluation Plan. Clause 21.04 The Employer shall supply a copy of the Joint Job Evaluation Manual to a probationary employee upon hiring. Clause 21.05 All jobs processed under the Joint Job Evaluation Plan shall be designated a Salary Group in the Salary Schedule "A", O.C.T. Unit, issued in conjunction with the Collective Agreement. Clause 21.06 In order to alleviate the special out-of-schedule rates, the following procedures shall apply:
Sample 1Sample 2Sample 3See All (24)
AutoNDA by SimpleDocs
JOINT EVALUATION. After 3 years of implementation a joint evaluation based on OECD standard criteria should take place in order to analyze the results of the Partnership.
Sample 1Sample 2
JOINT EVALUATION clause 21.01 provisions, which form the basis of the Joint Job evaluation plan, are contained in the collective Agreement and Job evaluation manual. The Job evaluation manual shall form an integral part of the collective Agreement.
Sample 1
JOINT EVALUATION. In the event that mice of Section 1(A)(2) are established, Lexicon shall: (i) evaluate and analyze the mice; (ii) provide Arena with a sufficient number of such mice, including an approximate equal number of male(s) and an approximate number of female(s) as maintained by Lexicon, if and when each gender is represented (but not more than 50% of the total mice established shall be provided to Arena) for Arena's evaluation and analysis; and (iii) conduct mutually-agreed to in vivo analysis of the In Vivo Compounds - Feasibility using such mice. The Parties shall jointly work together and share the results of their respective evaluations with each other. The objective of such evaluations and analyses shall be to determine the effect(s), if any, of the inclusion of the CART Technology Known GPCR receptor and/or the inclusion of the CART Technology Orphan GPCR receptor and/or the exclusion of the corresponding Known and Orphan GPCR mouse receptors, on the resulting mice. Each Party agrees to utilize reasonable efforts within a reasonable time frame to complete its evaluation and analysis, but in no event shall the respective evaluation and analysis exceed twelve (12) months from the birth of any gene-targeted mice of Section 1(A)(2). The Parties shall thereafter jointly discuss the results of the evaluations and analysis and determine, in good faith, whether to proceed to the Alliance Component of Section 1(B); to terminate the collaboration; or to jointly modify the collaboration. In the event that the Parties jointly decide to terminate the collaboration, the obligations of each Party of Section 1(A)(4)(ii) shall continue for a period of five (5) years from the date of such termination. The Parties agree to establish, in good faith, mutually acceptable criteria for the biological analyses to be conducted on the mice within ninety (90) days after the Effective Date, and to attach such criteria to the Final Agreement in the form of an appendix.
Sample 1
JOINT EVALUATION. In the event that Alliance mice of Section 1(B)(2) are established, Lexicon shall: (i) evaluate and analyze the mice; (ii) provide Arena with a sufficient number of such mice, including an approximate equal number of male(s) and an approximate number of female(s) as maintained by Lexicon, if and when each gender is represented (but not more than 50% of the total mice established shall be provided to Arena) for Arena's evaluation and analysis; and (iii) conduct mutually-agreed to in vivo analysis of the In Vivo Compounds - Alliance using such mice.. The Parties shall jointly work together and share the results of their respective evaluations with each other. The objective of such evaluations and analyses shall be to determine the effect(s), if any, of the CART Technology Alliance GPCR(s) on the resulting mice. Each Party agrees to utilize reasonable efforts within a reasonable time frame to complete its evaluation and analysis, but in no event shall the respective evaluation and analysis exceed twelve (12) months from the birth of any mice of Section 1(B)(2). The Parties, via the Steering Committee, shall thereafter jointly discuss the results of the evaluations and analysis and determine, in good faith, the ability to proceed to the Licensing Component of Section 2. The Parties agree to utilize the criteria for the biological analyses of Section 1(A)(3) for such.
Sample 1
JOINT EVALUATION. SulphCo and PC1 will jointly evaluate the PCI Report and determine their interest to further cooperate in the implementation of those findings of the PCI Report that will be accepted by SulphCo (such future cooperation, if applicable, being hereafter referred to as the "Cooperation").
Sample 1
JOINT EVALUATION 
Sample 1
AutoNDA by SimpleDocs

Related to JOINT EVALUATION

  • Independent Evaluation Buyer is an experienced and knowledgeable investor in the oil and gas business. Buyer has been advised by and has relied solely on its own expertise and legal, tax, title, reservoir engineering, environmental and other professional counsel concerning this transaction, the Properties, the value thereof and title thereto.

  • Trust Evaluation As of the Evaluation Time (a) on the last Business Day of each year, (b) on the day on which any Unit is tendered for redemption and (c) on any other day desired by the Trustee or requested by the Depositor, the Trustee shall: Add (i) all moneys on deposit in a Trust (excluding (1) cash, cash equivalents or Letters of Credit deposited pursuant to Section 2.01 hereof for the purchase of Contract Securities, unless such cash or Letters of Credit have been deposited in the Interest and Principal Accounts because of failure to apply such moneys to the purchase of Contract Securities pursuant to the provisions of Sections 2.01, 3.03 and 3.04 hereof and (2) moneys credited to the Reserve Account pursuant to Section 3.05 hereof), plus (ii) the aggregate Evaluation of all Securities (including Contract Securities and Reinvestment Securities) on deposit in such Trust as is determined by the Evaluator (such evaluations shall take into account and itemize separately (i) the cash on hand in the Trust or moneys in the process of being collected from matured interest coupons or bonds matured or called for redemption prior to maturity, (ii) the value of each issue of the Securities in the Trust on the bid side of the market as determined by the Evaluator pursuant to Section 4.01, and (iii) interest accrued thereon not subject to collection and distribution). For each such Evaluation there shall be deducted from the sum of the above (i) amounts representing any applicable taxes or governmental charges payable out of the respective Trust and for which no deductions shall have previously been made for the purpose of addition to the Reserve Account, (ii) amounts representing estimated accrued fees of the Trust and expenses of such Trust including but not limited to unpaid fees and expenses of the Trustee, the Evaluator, the Supervisor, the Depositor and bond counsel, in each case as reported by the Trustee to the Evaluator on or prior to the date of evaluation, (iii) any moneys identified by the Trustee, as of the date of the Evaluation, as held for distribution to Unitholders of record as of a Record Date or for payment of the Redemption Value of Units tendered prior to such date and (iv) unpaid organization costs in the estimated amount per Unit set forth in the Prospectus. The resulting figure is herein called a "Trust Fund Evaluation." The value of the pro rata share of each Unit of the respective Trust determined on the basis of any such evaluation shall be referred to herein as the "Unit Value."

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Quantitative Analysis Quantitative analysts develop and apply financial models designed to enable equity portfolio managers and fundamental analysts to screen potential and current investments, assess relative risk and enhance performance relative to benchmarks and peers. To the extent that such services are to be provided with respect to any Account which is a registered investment company, Categories 3, 4 and 5 above shall be treated as “investment advisory services” for purposes of Section 5(b) of the Agreement.”

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Account Details and Settlement Information Payments to Party A: Citibank, New York ABA No.: 021 000 089 Account No.: 4072-4601 Account Name: Morgan Stanley Capital Services Inc. Payments to Party B: Deutsche Bank ABA No.: 021001033 Account No: 01419663 Acct Name: XXXXX Xxnds Control - Stars West Ref: Morgan Stanley ABS Capital I Inc. Trust 2006-HE5

  • Evaluation 1. The purposes of evaluation provisions include providing employees with feedback, and employers and employees with the opportunity and responsibility to address concerns. Where a grievance proceeds to arbitration, the arbitrator must consider these purposes, and may relieve on just and reasonable terms against breaches of time limits or other procedural requirements.

Time is Money Join Law Insider Premium to draft better contracts faster.